Belantamab (GSK2857916) is a humanized IgG1 monoclonal antibody targeting BCMA (B-cell maturation antigen), also known as TNFRSF17. This antibody is conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) via a non-cleavable linker, forming the antibody-drug conjugate (ADC) Belantamab mafodotin. Upon binding to BCMA expressed on the surface of tumor cells, Belantamab mafodotin is internalized through receptor-mediated endocytosis. Inside the cell, the conjugate releases MMAF, which inhibits tubulin polymerization, leading to cell cycle arrest and subsequent induction of apoptosis in the tumor cells. This mechanism positions Belantamab mafodotin as a potent therapeutic agent for the investigation of multiple myeloma, particularly in cases of relapsed or refractory disease.
Belantamab (GSK2857916) is a humanized IgG1 monoclonal antibody targeting BCMA (B-cell maturation antigen), also known as TNFRSF17. This antibody is conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) via a non-cleavable linker, forming the antibody-drug conjugate (ADC) Belantamab mafodotin. Upon binding to BCMA expressed on the surface of tumor cells, Belantamab mafodotin is internalized through receptor-mediated endocytosis. Inside the cell, the conjugate releases MMAF, which inhibits tubulin polymerization, leading to cell cycle arrest and subsequent induction of apoptosis in the tumor cells. This mechanism positions Belantamab mafodotin as a potent therapeutic agent for the investigation of multiple myeloma, particularly in cases of relapsed or refractory disease.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
